Skip to content

BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis

Search Clinical Trials

Trial Objectives

For many people living with cystic fibrosis, there are treatments available called cystic fibrosis transmembrane conductance regulator (CFTR) modulators that can help treat the underlying cause of cystic fibrosis. However, more than 5,000 people living with cystic fibrosis have a change in both of their CFTR genes that makes them not expected to benefit from CFTR modulators.

The BEACON-CF clinical research study is exploring an investigational study drug called VX-522, a type of messenger RNA (mRNA) therapy, to see if it is safe and well tolerated for those who are not expected to benefit from CFTR modulators.

mRNA therapy is designed to send a message that tells cells (the building blocks of the body) to produce normal proteins that can do the job of proteins that are faulty or missing. If the investigational study drug is effective, it will tell cells in the lungs to create normal CFTR protein, which may improve the way the lungs work in people with cystic fibrosis.

VX-522 will be given as a single dose using a modified PARI nebulizer, an investigational medical device that turns liquid medications into a mist, which is then inhaled.

Who Can Participate

Adults aged 18-65 with cystic fibrosis who are not expected to benefit from CFTR modulators. Participants must have a forced expiratory volume in 1 second (FEV1) value of more than or equal to 40%. Participants also cannot have a history of solid organ or hematological transplantation. Additional eligibility criteria may apply.

Age: 18-65 Gender Any

Estimated Time Commitment

28 weeks with 8 in-person visits and 4 phone calls.

Payment & Reimbursement

Payment Provided

Travel Reimbursement Available

Trial Contact

For more information, contact:

Samantha Johnson

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Vertex Pharmaceuticals Inc.

Principal Investigators

Jennifer L. Taylor-Cousar

Jennifer L. Taylor-Cousar, MD, MSCS

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required